Skip to main content
CRS 2026 Annual Meeting & Exposition Main banner

Manufacturing and Process Scale-Up

All-in-one microfluidic manufacturing method of targeted lipid nanoparticles: showcase of in vivo CAR T production

Dzhangar Dzhumashev – Post-doc, University of Geneva; Valérie Dutoit-Vallotton – Privat-docent, University of Geneva; Gaspard Pardon – Head of Unit, EPFL; Denis Migliorini – Professor, University of Geneva
Introduction:

Microfluidic mixing is widely used for lab-scale lipid nanoparticle (LNP) production [1], but integration of formulation, solvent removal, and ligand conjugation into a single controllable workflow has never been addressed. Hence, we developed a modular multi-step microfluidic platform that combines LNP formation with on-line solvent removal and conjugation to enable screening-oriented generation of effective ligand-coated LNP. With this platform, anti-CD5 LNP with mRNA of anti-GD2 and anti-PTPRZ1 CAR constructs were produced and CAR T generation validated ex vivo in Jurkat cells, human and murine primary T cells, and in vivo in C57BL/6 mice.

Learning Objectives:

  • Describe an integrated microfluidic workflow for LNP formation, solvent removal, and ligand conjugation.
  • Evaluate how an integrated microfluidic platform improves preparation, optimizing time, quality, and resources.
  • Explain the potential of targeted LNP delivery as a scalable alternative approach for CAR T cell generation.